Home » Stocks » IMPL

Impel NeuroPharma, Inc. (IMPL)

Impel NeuroPharma will go public soon. The estimated IPO date is April 23, 2021.
Stock Price: $14.00 - $16.00
Current IPO price range
Market Cap 291.22M
Revenue (ttm) n/a
Net Income (ttm) -46.32M
Shares Out 19.41M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Impel NeuroPharma has filed to raise $75 million in an IPO to bring a migraine drug to market. The candidate, Trudhesa, is delivered using a metered dose device intended to get the active ingredient int...

1 week ago - FiercePharma

Impel NeuroPharma, Inc. has filed to go public with an IPO on the NASDAQ.

2 weeks ago - SEC

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

1 month ago - Zacks Equity Research

About IMPL

Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. We have designed our proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology to target the vascular-rich upper nasal cavity, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, pro... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Apr 23, 2021
CEO
Adrian Adams
Employees
59
Stock Exchange
NASDAQ
Ticker Symbol
IMPL
Full Company Profile

Financial Performance

Financial Statements